Showing results (2551-2560 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|January 17, 2018
Sphingadienes show therapeutic efficacy in neuroblastoma in vitro and in vivo by targeting the AKT signaling pathwayPiming Zhao, Ana E Aguilar, Joanna Y Lee, et al.
Investigational New Drugs|December 14, 2017
Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov databaseD Shepshelovich, H Goldvaser, L Wang, et al.
Investigational New Drugs|December 19, 2017
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancerEvan Y Yu, Susan L Ellard, Sebastien J Hotte, et al.
Investigational New Drugs|May 31, 2022
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 studyStergios J Moschos, Shahneen Sandhu, Karl D Lewis, et al.
Investigational New Drugs|July 3, 2021
Serine hydroxymethyltransferase 2: a novel target for human cancer therapyMin Xie, Dong-Sheng Pei
Investigational New Drugs|July 1, 2021
Development and validation of a ferroptosis-related prognostic model in pancreatic cancerChen-Jie Qiu, Xue-Bing Wang, Zi-Ruo Zheng, et al.
Investigational New Drugs|January 7, 2021
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879David I Quinn, Denice D Tsao-Wei, Przemyslaw Twardowski, et al.
Investigational New Drugs|January 7, 2021
Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective studyLiu-Fang Ye, Chao Ren, Long Bai, et al.
Investigational New Drugs|January 7, 2021
The flavonoid luteolin suppresses infantile hemangioma by targeting FZD6 in the Wnt pathwayYujian Dai, Huiming Zheng, Zhen Liu, et al.
Investigational New Drugs|January 9, 2021
Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteersLei Li, Yu-Xia Xiang, Guo-Ping Yang, et al.
Pageof 372